847950-09-8

847950-09-8 structure

Name: TC-S 7003
Chemical Name: 6-(2,6-Dimethylphenyl)-2-{[4-(4-methyl-1-piperazinyl)phenyl]amino }pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-one
CAS Number: 847950-09-8
Molecular Formula: C₃₁H₃₀N₈O
Molecular Weight: 530.62300
Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK Src
Create Date: 2016-06-15 02:18:46
Modify Date: 2024-01-20 15:59:28
Lck Inhibitor is a new class of compounds that are potent inhibitors of Lck with an IC50 value of 7 nM.IC50 Value: 7 nM [1]Target: Lckin vitro: Lck Inhibitor (compound 25) exhibited good potency in the T-cell receptor-induced IL-2 secretion assay (IL- 2) and also inhibited subsequent T-cell proliferation (T-cell prolif.) in the same human T -cells.in vivo: A once daily dose of 25was administered orally at 10, 30, and 60 mg/kg from day 9 today 17. Paw volume was measured daily from day 9 through day 18. The compound showed a dose-dependent inhibition of arthritis, with an ED50 estimated at 24 mg/kg (Figure 6). Based on the measured plasma levels from the three dose groups, the exposure of 25 at the ED50 was estimated to be 2.7 μM·h (Cmax≈ 0.7 μM) [1].Clinical trial: N/A

Name	6-(2,6-Dimethylphenyl)-2-{[4-(4-methyl-1-piperazinyl)phenyl]amino }pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-one
Synonyms	Lck Inhibitor

Description	Lck Inhibitor is a new class of compounds that are potent inhibitors of Lck with an IC50 value of 7 nM.IC50 Value: 7 nM [1]Target: Lckin vitro: Lck Inhibitor (compound 25) exhibited good potency in the T-cell receptor-induced IL-2 secretion assay (IL- 2) and also inhibited subsequent T-cell proliferation (T-cell prolif.) in the same human T -cells.in vivo: A once daily dose of 25was administered orally at 10, 30, and 60 mg/kg from day 9 today 17. Paw volume was measured daily from day 9 through day 18. The compound showed a dose-dependent inhibition of arthritis, with an ED50 estimated at 24 mg/kg (Figure 6). Based on the measured plasma levels from the three dose groups, the exposure of 25 at the ED50 was estimated to be 2.7 μM·h (Cmax≈ 0.7 μM) [1].Clinical trial: N/A
Related Catalog	Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Src Research Areas >> Inflammation/Immunology
References	[1]. Martin, Matthew W.; Newcomb, John; Nunes, Joseph J.; et al. Structure-Based Design of Novel 2-Amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as Potent and Orally Active Inhibitors of Lymphocyte Specific Kinase (Lck): Synthesis, SAR, and In Vivo Anti-Inflammatory Activity. Journal of Medicinal Chemistry (2008), 51(6), 1637-1648. [2]. Liew, Chin Y.; Ma, Xiao H.; Liu, Xianghui; Yap, Chun W. SVM Model for Virtual Screening of Lck Inhibitors. Journal of Chemical Information and Modeling (2009), 49(4), 877-885.